A sustainable ROS cycle generator (SRCG) for tumor chemodynamic therapy.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Chemodynamic therapy (CDT) shows promise for cancer treatment but is limited by insufficient reactive oxygen species (ROS) generation.
• Developing strategies to enhance intratumoral ROS production is crucial for advancing CDT.
• Overcoming these limitations is key to translating CDT into effective clinical applications.

Purpose of the Study:

• To develop a sustainable reactive oxygen species cycle generator (SRCG) for high-efficiency tumor chemodynamic therapy.
• To create a nanoreactor capable of continuous ROS production to overcome the limitations of current CDT strategies.
• To investigate the potential of this novel approach for effective tumor treatment.

Main Methods:

• A porous metal-organic framework (Cu-ZIF8) was used as a carrier for glucose oxidase (GOX) and hyaluronidase (HAase).
• The nanoreactor (Cu-ZIF8@GOX@HAase, CZGH) releases enzymes under acidic conditions to hydrolyze glucose and hyaluronic acid, generating ROS.
• The system was evaluated for its ability to degrade the extracellular matrix, enhance tumor permeability, and sustain ROS production in vitro and in vivo.

Main Results:

• The developed nanoreactor (CZGH) demonstrated efficient and continuous ROS generation.
• CZGH effectively degraded the extracellular matrix, improving tumor permeability and relieving hypoxia.
• In vitro and in vivo studies in a breast tumor mouse model confirmed the effectiveness of the SRCG system in promoting tumor cell death.

Conclusions:

• The sustainable ROS cycle generator (SRCG) offers a promising strategy for enhancing chemodynamic therapy.
• This novel nanoreactor system overcomes key challenges in ROS generation for improved tumor treatment.
• The findings highlight the potential of CZGH as a groundbreaking approach for extensive tumor therapy.